In addition, although CD8+ DCs is essential to induce CD8+ T cells responses with our K3-SPG therapy, it needs future studies to investigate whether the tumor phagocytes with K3-SPG directly present tumor antigen to the CD8+ T cells. Here, CD8A is linked to neoplasm.